Agenus Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AGEN Nasdaq 2834 www.agenusbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Agenus Inc.

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer - Aug 6th, 2026 5:30 am
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates - Aug 4th, 2026 6:50 am
Agenus (AGEN) Earnings Expected to Grow: Should You Buy? - Jul 30th, 2026 8:00 am
Agenus to Provide Second Quarter 2026 Financial Report and Development Update - Jul 28th, 2026 2:30 pm
Do Options Traders Know Something About Agenus Stock We Don't? - Jul 23rd, 2026 11:11 am
Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing - Jul 17th, 2026 2:11 pm
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 - Jul 17th, 2026 8:28 am
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot - Jul 14th, 2026 9:57 am
Agenus stock doubles as biotech narrows Phase 3 bet - Jul 14th, 2026 8:17 am
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last? - Jul 14th, 2026 6:15 am
Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed? - Jul 14th, 2026 4:15 am
AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment - Jul 13th, 2026 12:25 pm
Agenus shares surge as company secures up to $340M to advance colon cancer trial - Jul 13th, 2026 10:53 am
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing - Jul 13th, 2026 8:02 am
Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN) - Jul 13th, 2026 6:25 am
Agenus surges on study pivot; Apnimed lines up an IPO - Jul 13th, 2026 5:46 am
Agenus rises premarket; Micron, Western Digital slide - Jul 13th, 2026 4:59 am
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer - Jul 13th, 2026 4:00 am
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026 - Jul 6th, 2026 5:30 am
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves - Jun 16th, 2026 10:06 am